FDA ENANTIOMER MARKETING EXCLUSIVITY POLICY MAY BE REVISED, AGENCY ANNOUNCES; WYETH/INTERNEURON REDUX EXCLUSIVITY DETERMINATION TO BE MADE BY PTO, FDA SAYS

FDA is soliciting comments on the appropriate exclusivity period for single-isomer versions of previously marketed racemic products, the agency announced in a Jan. 15 Federal Register notice.